BioSpace News Archive

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its business update and financial results for the third quarter ended September 30, 2022.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended September 30, 2022.

BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the three and nine months ended September 30, 2022.

Outset Medical, Inc., a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced that members of management will participate in fireside chats at two upcoming investor conferences.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted nine new employees options to purchase a total of 13,700 shares of the Company’s common stock at an exercise price per share of $24.69, which was the closing price on November 8, 2022, and restricted stock units to acquire a total of 6,850 shares of the Company’s common stock.

Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2022.

Acasti Pharma Inc., a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced that Jan D’Alvise, President and CEO of Acasti Pharma will be presenting virtually at the Q4 Investor Summit.

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and nine months ended September 30, 2022 and provided a business update.

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and announced operational progress and cash position (unaudited) for the third quarter of 2022.

Precision Optics Corporation, Inc. (OTCQB: PEYE; PEYED) (the “Company”) today announced that it has scheduled a conference call to discuss first quarter of fiscal year 2023 financial results on Monday, November 14, 2022, at 5:00pm ET.